• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

透明细胞肾细胞癌中肿瘤细胞的程序性死亡受体配体1(PD-L1)表达模式及其与CD8肿瘤浸润淋巴细胞的关联

PD-L1 expression patterns in tumour cells and their association with CD8 tumour infiltrating lymphocytes in clear cell renal cell carcinoma.

作者信息

Zhu Qian, Cai Mu-Yan, Weng De-Sheng, Zhao Jing-Jing, Pan Qiu-Zhong, Wang Qi-Jing, Tang Yan, He Jia, Li Min, Xia Jian-Chuan

机构信息

Collaborative Innovation Center for Cancer Medicine, State Key Laboratory of Oncology in South China, Sun Yat-Sen University Cancer Center, Guangzhou, P. R. China.

Department of Biotherapy, Sun Yat-Sen University Cancer Center, Guangzhou 510060, People's Republic of China.

出版信息

J Cancer. 2019 Jan 29;10(5):1154-1161. doi: 10.7150/jca.29052. eCollection 2019.

DOI:10.7150/jca.29052
PMID:30854124
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6400669/
Abstract

: To evaluate the tumour cell PD-L1 (TC-PD-L1) expression patterns in the local microenvironment of clear cell renal cell carcinoma (ccRCC). : 30 fresh primary ccRCC tissues were used to detect the association between TC-PD-L1 and CD8TILs at mRNA level. The incubation experiment was used to confirm the association between extrinsic TC-PD-L1 expression and IFNγ. A cohort of 135 ccRCC patients treated between January 2009 and August 2013 was included for survival analysis. : Our results confirmed that ccRCC cell lines were capable of expressing PD-L1. The incubation experiment demonstrated the positive correlation of TC-PD-L1 expression with interferon-gamma (IFNγ). Additionally, survival analysis was investigated in 135 ccRCC patients and found no independent correlation of TC-PD-L1 expression in multivariate analysis, whereas more distinct prognostic differences were detected when TC-PD-L1-positive ccRCC were sub-classified as with or without CD8 T cell infiltration. : The intrinsic and extrinsic expression patterns are both detected in ccRCC. High positive rate of TC-PD-L1 correlated closely to the strong infiltration of CD8 TILs. TC-PD-L1-positive ccRCC patients with abundant CD8 TILs infiltration confer the high risk of death and disease relapse.

摘要

评估透明细胞肾细胞癌(ccRCC)局部微环境中肿瘤细胞程序性死亡受体配体1(TC-PD-L1)的表达模式。使用30例新鲜原发性ccRCC组织在mRNA水平检测TC-PD-L1与CD8肿瘤浸润淋巴细胞(CD8TILs)之间的关联。采用孵育实验证实外源性TC-PD-L1表达与干扰素γ(IFNγ)之间的关联。纳入2009年1月至2013年8月期间接受治疗的135例ccRCC患者队列进行生存分析。我们的结果证实ccRCC细胞系能够表达PD-L1。孵育实验证明TC-PD-L1表达与干扰素γ(IFNγ)呈正相关。此外,对135例ccRCC患者进行生存分析,在多变量分析中发现TC-PD-L1表达无独立相关性,而当TC-PD-L1阳性的ccRCC根据有无CD8 T细胞浸润进行亚分类时,检测到更明显的预后差异。ccRCC中检测到内在和外在表达模式。TC-PD-L1的高阳性率与CD8 TILs的强浸润密切相关。CD8 TILs浸润丰富的TC-PD-L1阳性ccRCC患者具有高死亡风险和疾病复发风险。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/adab/6400669/36c53ffb20b2/jcav10p1154g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/adab/6400669/0009e0b2991e/jcav10p1154g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/adab/6400669/8cd1713b2734/jcav10p1154g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/adab/6400669/379100bfdd03/jcav10p1154g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/adab/6400669/36c53ffb20b2/jcav10p1154g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/adab/6400669/0009e0b2991e/jcav10p1154g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/adab/6400669/8cd1713b2734/jcav10p1154g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/adab/6400669/379100bfdd03/jcav10p1154g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/adab/6400669/36c53ffb20b2/jcav10p1154g004.jpg

相似文献

1
PD-L1 expression patterns in tumour cells and their association with CD8 tumour infiltrating lymphocytes in clear cell renal cell carcinoma.透明细胞肾细胞癌中肿瘤细胞的程序性死亡受体配体1(PD-L1)表达模式及其与CD8肿瘤浸润淋巴细胞的关联
J Cancer. 2019 Jan 29;10(5):1154-1161. doi: 10.7150/jca.29052. eCollection 2019.
2
HHLA2 and PD-L1 co-expression predicts poor prognosis in patients with clear cell renal cell carcinoma.HHLA2 和 PD-L1 共表达预示着透明细胞肾细胞癌患者预后不良。
J Immunother Cancer. 2020 Jan;8(1). doi: 10.1136/jitc-2019-000157.
3
Tumor-Infiltrating and Peripheral Blood T-cell Immunophenotypes Predict Early Relapse in Localized Clear Cell Renal Cell Carcinoma.肿瘤浸润和外周血 T 细胞免疫表型预测局限性透明细胞肾细胞癌的早期复发。
Clin Cancer Res. 2017 Aug 1;23(15):4416-4428. doi: 10.1158/1078-0432.CCR-16-2848. Epub 2017 Feb 17.
4
Prognostic value of tumor PD-L1 expression combined with CD8 tumor infiltrating lymphocytes in high grade serous ovarian cancer.肿瘤 PD-L1 表达联合 CD8 肿瘤浸润淋巴细胞对高级别浆液性卵巢癌的预后价值。
Int Immunopharmacol. 2017 Nov;52:7-14. doi: 10.1016/j.intimp.2017.08.017. Epub 2017 Aug 31.
5
Transcriptomic Correlates of Tumor Cell PD-L1 Expression and Response to Nivolumab Monotherapy in Metastatic Clear Cell Renal Cell Carcinoma.肿瘤细胞 PD-L1 表达与纳武单抗单药治疗转移性透明细胞肾细胞癌反应的转录组学相关性。
Clin Cancer Res. 2022 Sep 15;28(18):4045-4055. doi: 10.1158/1078-0432.CCR-22-0923.
6
Prognostic significance of the programmed death ligand 1 expression in clear cell renal cell carcinoma and correlation with the tumor microenvironment and hypoxia-inducible factor expression.程序性死亡配体1表达在透明细胞肾细胞癌中的预后意义及其与肿瘤微环境和缺氧诱导因子表达的相关性
Diagn Pathol. 2018 Aug 25;13(1):60. doi: 10.1186/s13000-018-0742-8.
7
Programmed cell death ligand 1 and tumor-infiltrating lymphocyte status in patients with renal cell carcinoma and sarcomatoid dedifferentiation.肾细胞癌伴肉瘤样去分化患者的程序性细胞死亡配体1及肿瘤浸润淋巴细胞状态
Cancer. 2017 Dec 15;123(24):4823-4831. doi: 10.1002/cncr.30937. Epub 2017 Aug 22.
8
Prognostic significance of PD-L1 expression and CD8+ T cell infiltration in pulmonary neuroendocrine tumors.PD-L1表达和CD8 + T细胞浸润在肺神经内分泌肿瘤中的预后意义
Diagn Pathol. 2018 May 22;13(1):30. doi: 10.1186/s13000-018-0712-1.
9
Prognostic value of PD-1 and PD-L1 expression in patients with metastatic clear cell renal cell carcinoma.PD-1和PD-L1表达在转移性透明细胞肾细胞癌患者中的预后价值。
Urol Oncol. 2018 Nov;36(11):499.e9-499.e16. doi: 10.1016/j.urolonc.2018.07.003. Epub 2018 Aug 18.
10
Programmed Death Ligand 1 Indicates Pre-Existing Adaptive Immune Response by Tumor-Infiltrating CD8 T Cells in Non-Small Cell Lung Cancer.程序性死亡配体 1 表明非小细胞肺癌肿瘤浸润 CD8 T 细胞存在预先存在的适应性免疫反应。
Int J Mol Sci. 2019 Oct 17;20(20):5138. doi: 10.3390/ijms20205138.

引用本文的文献

1
PD1/PD-L1 blockade in clear cell renal cell carcinoma: mechanistic insights, clinical efficacy, and future perspectives.透明细胞肾细胞癌中PD1/PD-L1阻断:机制见解、临床疗效及未来展望。
Mol Cancer. 2024 Jul 16;23(1):146. doi: 10.1186/s12943-024-02059-y.
2
Genes associated with inflammation for prognosis prediction for clear cell renal cell carcinoma: a multi-database analysis.用于透明细胞肾细胞癌预后预测的炎症相关基因:多数据库分析
Transl Cancer Res. 2023 Oct 31;12(10):2629-2645. doi: 10.21037/tcr-23-1183. Epub 2023 Oct 12.
3
APPL1 Is a Prognostic Biomarker and Correlated with Treg Cell Infiltration via Oxygen-Consuming Metabolism in Renal Clear Cell Carcinoma.

本文引用的文献

1
Programmed death ligand 1 as an indicator of pre-existing adaptive immune responses in human hepatocellular carcinoma.程序性死亡配体1作为人类肝细胞癌中预先存在的适应性免疫反应的指标。
Oncoimmunology. 2016 May 13;5(7):e1181252. doi: 10.1080/2162402X.2016.1181252. eCollection 2016 Jul.
2
PD-L1 expression in renal cell carcinoma clear cell type is related to unfavorable prognosis.肾细胞癌透明细胞型中的程序性死亡受体配体1(PD-L1)表达与不良预后相关。
Diagn Pathol. 2015 Oct 15;10:189. doi: 10.1186/s13000-015-0414-x.
3
Clinicopathologic Analysis of PD-L1 and PD-L2 Expression in Renal Cell Carcinoma: Association with Oncogenic Proteins Status.
APPL1 是肾透明细胞癌的预后生物标志物,通过耗氧代谢与 Treg 细胞浸润相关。
Oxid Med Cell Longev. 2023 Feb 17;2023:5885203. doi: 10.1155/2023/5885203. eCollection 2023.
4
Prognostic and predictive biomarkers for immunotherapy in advanced renal cell carcinoma.晚期肾细胞癌免疫治疗的预后和预测生物标志物。
Nat Rev Urol. 2023 Mar;20(3):133-157. doi: 10.1038/s41585-022-00676-0. Epub 2022 Nov 21.
5
Comprehensive analysis of expression and prognostic value in kidney renal papillary cell carcinoma and clear cell carcinoma.肾乳头状细胞癌和透明细胞癌中表达及预后价值的综合分析。
Front Mol Biosci. 2022 Sep 16;9:988777. doi: 10.3389/fmolb.2022.988777. eCollection 2022.
6
Imaging of Clear Cell Renal Carcinoma with Immune Checkpoint Targeting Aptamer-Based Probe.基于免疫检查点靶向适体的探针用于透明细胞肾细胞癌的成像
Pharmaceuticals (Basel). 2022 Jun 1;15(6):697. doi: 10.3390/ph15060697.
7
Immunotherapy: A new standard in the treatment of metastatic clear cell renal cell carcinoma.免疫疗法:转移性透明细胞肾细胞癌治疗的新标准。
World J Clin Oncol. 2022 Jan 24;13(1):28-38. doi: 10.5306/wjco.v13.i1.28.
8
Prognostic Value of Long Noncoding RNA DLEU2 and Its Relationship with Immune Infiltration in Kidney Renal Clear Cell Carcinoma and Liver Hepatocellular Carcinoma.长链非编码RNA DLEU2在肾透明细胞癌和肝细胞癌中的预后价值及其与免疫浸润的关系
Int J Gen Med. 2021 Nov 11;14:8047-8064. doi: 10.2147/IJGM.S336428. eCollection 2021.
9
Integrated mRNA and miRNA Transcriptomic Analyses Reveals Divergent Mechanisms of Sunitinib Resistance in Clear Cell Renal Cell Carcinoma (ccRCC).整合的mRNA和miRNA转录组分析揭示了透明细胞肾细胞癌(ccRCC)中舒尼替尼耐药的不同机制。
Cancers (Basel). 2021 Aug 31;13(17):4401. doi: 10.3390/cancers13174401.
10
Prognostic Relevance of CD4, CD8 and FOXP3 TILs in Oral Squamous Cell Carcinoma and Correlations with PD-L1 and Cancer Stem Cell Markers.CD4、CD8和FOXP3肿瘤浸润淋巴细胞在口腔鳞状细胞癌中的预后相关性及其与程序性死亡受体1配体(PD-L1)和癌症干细胞标志物的相关性
Biomedicines. 2021 Jun 8;9(6):653. doi: 10.3390/biomedicines9060653.
肾细胞癌中PD-L1和PD-L2表达的临床病理分析:与致癌蛋白状态的关联
Ann Surg Oncol. 2016 Feb;23(2):694-702. doi: 10.1245/s10434-015-4903-7.
4
Differential Expression of PD-L1 between Primary and Metastatic Sites in Clear-Cell Renal Cell Carcinoma.在肾透明细胞癌原发灶与转移灶中 PD-L1 的差异表达。
Cancer Immunol Res. 2015 Oct;3(10):1158-64. doi: 10.1158/2326-6066.CIR-15-0043. Epub 2015 May 26.
5
Classifying Cancers Based on T-cell Infiltration and PD-L1.基于T细胞浸润和PD-L1对癌症进行分类
Cancer Res. 2015 Jun 1;75(11):2139-45. doi: 10.1158/0008-5472.CAN-15-0255.
6
Differential Expression of Immune-Regulatory Genes Associated with PD-L1 Display in Melanoma: Implications for PD-1 Pathway Blockade.与黑色素瘤中PD-L1表达相关的免疫调节基因的差异表达:对PD-1通路阻断的意义。
Clin Cancer Res. 2015 Sep 1;21(17):3969-76. doi: 10.1158/1078-0432.CCR-15-0244. Epub 2015 May 5.
7
Correlation of PD-L1 tumor expression and treatment outcomes in patients with renal cell carcinoma receiving sunitinib or pazopanib: results from COMPARZ, a randomized controlled trial.比较研究:舒尼替尼或帕唑帕尼治疗的肾细胞癌患者的 PD-L1 肿瘤表达与治疗结果的相关性:一项随机对照试验的结果。
Clin Cancer Res. 2015 Mar 1;21(5):1071-7. doi: 10.1158/1078-0432.CCR-14-1993. Epub 2014 Dec 23.
8
Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial.纳武单抗治疗转移性肾细胞癌:一项随机II期试验的结果
J Clin Oncol. 2015 May 1;33(13):1430-7. doi: 10.1200/JCO.2014.59.0703. Epub 2014 Dec 1.
9
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients.癌症患者对抗PD-L1抗体MPDL3280A反应的预测性相关因素。
Nature. 2014 Nov 27;515(7528):563-7. doi: 10.1038/nature14011.
10
PD-L1 Expression in Clear Cell Renal Cell Carcinoma: An Analysis of Nephrectomy and Sites of Metastases.PD-L1 表达在肾透明细胞癌中的表达:肾切除术和转移部位的分析。
J Cancer. 2014 Jan 24;5(3):166-72. doi: 10.7150/jca.8167. eCollection 2014.